Avastin pockets another Priority Review label

Share this article:

Roche subsidiary Genentech has landed its second Priority Review label in two weeks for cancer drug Avastin. This week's status was tagged to a proposed indication for patients with recurring platinum-resistant ovarian cancer, paired with chemotherapy. Last week's Priority Review status was for patients with persistent, recurrent or metastatic cervical cancer, and was also paired with chemotherapy.

Chief medical officer and head of global product development Sandra Horning said in a statement that an approved ovarian cancer indication could be critical because “the majority of women with ovarian cancer will become resistant to platinum therapy and a quarter of women will have platinum-resistant disease at the time of first recurrence.”

The FDA is expected to vote yea or nay on the indication by November 19.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions